Key Highlights:
- Eli Lilly and Co (LLY, Financial) sees a 16% share price surge, driven by promising diabetes drug trials.
- Analysts forecast a potential upside of 14.87% with an average price target of $1,016.05.
- GuruFocus projects a 27.34% potential gain based on the estimated GF Value.
Eli Lilly and Company (LLY) has recently been on a robust upward trajectory, catching investors' attention with its innovative treatment developments. The pharmaceutical giant has seen its share price soar by 16%, a testament to the positive results from its diabetes drug trials. With major advancements anticipated by 2025, particularly in the fields of diabetes and obesity medications, Eli Lilly is poised to solidify its position as a strong asset in Ken Fisher (Trades, Portfolio)'s well-regarded portfolio.
Wall Street Analysts Forecast
Analyzing the forecasts from 25 seasoned Wall Street analysts, Eli Lilly and Co (LLY, Financial) receives an average target price of $1,016.05. This figure is accompanied by a high estimate of $1,190.00 and a low of $800.00, suggesting a notable potential upside of 14.87% from its current trading price of $884.54. For a more comprehensive breakdown, interested investors can visit the Eli Lilly and Co (LLY) Forecast page on GuruFocus.
Additionally, consensus ratings from 29 brokerage firms place Eli Lilly and Co (LLY, Financial) at an average brokerage recommendation of 1.9, aligning with an "Outperform" status. The rating metric spans from 1 to 5, with 1 representing a Strong Buy and 5 indicating a Sell recommendation.
GF Value Estimates
According to GuruFocus estimates, the projected GF Value for Eli Lilly and Co (LLY, Financial) in the coming year stands at $1,126.41. This estimation implies a potential upside of 27.34% from the current price of $884.54. The GF Value represents GuruFocus' fair value estimation, derived from historical trading multiples, past business performance, and future growth projections. For further insights into Eli Lilly's financial standing, the Eli Lilly and Co (LLY) Summary page offers detailed data and analysis.
